Heart failure & cardiomyopathiesDiagnostic or prognostic study
Incremental Value of C-Reactive Protein to the MEESSI Acute Heart Failure Risk Score
- Prognostic study (prospective multicentre cohort with external validation)
- central adjudication
- independent retrospective single-centre validation cohort
Authors' conclusion
Quantifying inflammation using CRP concentration provided incremental value in AHF risk stratification using the established MEESSI model.
Study context
- Population
- Patients with centrally adjudicated acute heart failure (AHF) (BASEL V)validation cohort n = 575
- Participants
- 1,208 patients
- Comparison
- Extended MEESSI model vs recalibrated MEESSI model
- Outcome
- Prognostic accuracy for 30-day mortality (c-statistic)
- Follow-up
- 30 days
Performance
As reported in the abstract
30-day mortality, c-statistic
| Test or model | c-statistic |
|---|---|
| Extended MEESSI | 0.83 (95% CI 0.79-0.87) |
| Recalibrated MEESSI | 0.79 (95% CI 0.75-0.83) |
- Extended MEESSI vs Recalibrated MEESSI: P = 0.013
Further findings
Patients stratified into lowest risk group
- Calibration of extended model
- 1.00 (95% CI 0.81-1.19) · Calibration slope · Calibration intercept 0.0 (95% CI −0.22 to 0.22)
Independent validation cohort
- Results confirmed in the independent validation cohort (n = 575)
Original publication
Incremental Value of C-Reactive Protein to the MEESSI Acute Heart Failure Risk Score. Eur J Heart Fail. Published 23 June 2024. doi:10.1002/ejhf.3349
Summarised from the published abstract; every number is checked against it